Utilizing Xenogeneic Cells As a Therapeutic Agent for Treating Diseases

Chi-Ping Huang¹, Chi-Yu Yang² and Chih-Rong Shyr³

Abstract

The utilization of biologically produced cells to treat diseases is a revolutionary invention in modern medicine after chemically synthesized small molecule drugs and biochemically made protein drugs. Cells are basic units of life with diverse functions in mature and developing organs, which biological properties could be utilized as a promising therapeutic approach for currently intractable and incurable diseases. Xenogeneic cell therapy utilizing animal cells other than human for medicinal purpose has been studied as a new way of treating diseases. Xenogeneic cell therapy is considered as a potential regenerative approach to fulfill current unmet medical needs because xenogeneic cells could be isolated from different animal organs and expanded ex vivo as well as maintain the characteristics of original organs, providing a versatile and plenty cell source for cell-based therapies beside autologous and allogeneic sources. The swine species is considered the most suitable source because of the similarity with humans in size and physiology of many organs in addition to the economic and ethical reasons plus the possibility of genetic modification. This review discusses the old proposed uses of xenogeneic cells such as xenogeneic pancreatic islet cells, hepatocytes and neuronal cells as a living drug for the treatment of degenerative and organ failure diseases. Novel applications of xenogeneic mesenchymal stroma cells and urothelial cells are also discussed. There are formidable immunological barriers toward successful cellular xenotransplantation in clinic despite major progress in the development of novel immunosuppression regimens and genetically multimodified donor pigs. However, immunological barriers could be turn into immune boosters by using xenogeneic cells of specific tissue types as a novel immunotherapeutic agent to elicit bystander antitumor immunity due to rejection immune responses. Xenogeneic cells have the potential to become a safe and efficacious option for intractable diseases and hard-to-treat cancers, adding a new class of cellular medicine in our drug armamentarium.

Keywords

rejection, xenoantigen, immunosuppression, neoantigen, antitumor immunity

Introduction

Cell therapy is a therapeutic approach that uses a biological product with therapeutic effect, derived from living cells of autologous, allogeneic or xenogeneic sources with the aim of preventing, treating or mitigating a disease¹. The U.S. Food and Drug Administration (FDA) also defines somatic-cell therapy as the administration to humans of autologous, allogeneic, or xenogeneic living somatic cells that have been manipulated or processed to change their biologic characteristics². Cellular therapies involving autologous or allogeneic use of cells have been applied in clinics as approve therapies. Autologous chimeric antigen receptor (CAR) T cell therapy has been validated and effective in treating relapsed and refractory hematological malignancies³,⁴, and allogeneic (or donor derived) expanded adipose-derived mesenchymal stem/stromal cells (eASCs) are clinically used for the treatment of complex perianal fistulas in adult Crohn’s disease patients⁵. There are many types of cell therapies in the experimental and clinical stages, paving the medicine revolution of cellular drugs after small molecule drugs and protein drugs. The development of human autologous or

¹ Department of Urology, School of Medicine, China Medical University and Hospital, Taichung, Taiwan
² Animal Technology Research Center/Division of Animal Technology, Agriculture Technology Research Institute, Miaoli, Taiwan
³ Sex Hormone Research Center, Department of Medical Laboratory Science and Biotechnology, China Medical University and Hospital, Taichung, Taiwan

Submitted: January 26, 2021. Revised: March 19, 2021. Accepted: April 5, 2021.

Corresponding Author:
Chih-Rong Shyr, Sex Hormone Research Center, Departments of Medical Laboratory Science and Biotechnology, China Medical University and Hospital, Taichung 40404, Taiwan.
Email: chshyr@mail.cmu.edu.tw
Xenogeneic cells as a cellular medicine
allogeneic cell therapy into more clinical applications is limited by the amount and availability of suitable functional and specialized cells to meet the general clinical needs since autologous cells can be only used in one individual and there are limited donated allogeneic cells. In addition, the use of allogeneic stem cell–derived cell is still challenged with the ability to precisely direct stem cells into functional specialized cells. However, xenogeneic cells could be isolated and expanded from primary cultures of tissues, and thus the cell fate is committed and specialized. Hence, xenogeneic cell therapy provides a promising new option by using the cells from different tissues of animals as a source for treating human diseases.

Xenogeneic cell therapy is a form of xenotransplantation, which, according to the definition of FDA, is considered as any procedure that involves the transplantation, implantation or infusion into a human recipient of either (a) live cells, tissues, or organs from a nonhuman animal source, or (b) human body fluids, cells, tissues, or organs that have had ex vivo contact with live nonhuman animal cells, tissues or organs. Furthermore, based on FDA’s interpretation of Section 506(g) of the Food, Drug, and Cosmetic Act (as added by Section 3033 of the 21st Century Cures Act), xenogeneic cell products may also meet the definition of a regenerative medicine therapy and can be eligible for Expedited Programs for Regenerative Medicine Therapies for Serious Conditions (RMAT) designation. European Medicines Agency (EMA) also classifies xenogeneic living cells as Advanced Therapy Medicinal Products (ATMPs). Organ xenotransplantation has been viewed as a potential solution to the existing shortage of human organs for transplantation, but challenged with immunological barriers cross species for successful clinical application. Xenogeneic cell therapy uses animal cells not solid organs for therapeutic purpose could be a more diverse and feasible medical intervention to treat diseases such as diabetes and some degenerative disorders, as demonstrated in pre-clinical animal models and clinical trials (reviewed in Meier et al. and Ekser et al.). That is because that xenogeneic cells face less rejection responses due to avasculation nature and the time period during cell product manufacturing, allowing for safety check the microbiological status. In addition, due to the bounty supply of edible animal sources such as pigs, cattle, and sheep for xenogeneic cell production, it is highly feasible clinically to use xenogeneic cells as a therapeutic agent, a drug that could be administered repeatedly and metabolized by the body for the diagnosis, cure, mitigation, treatment, or prevention of diseases as small molecule drugs and protein drugs. And as small molecule drugs and protein drugs, in order to be used in clinics, xenogeneic cells must go through a rigorous evaluation of safety, quality, and effectiveness before they can be utilized to treat diseases.

### Porcine Tissues Provide an Ideal Animal Source for Xenogeneic Cell Therapy

From an ethical and societal perspective, swine species is considered as the most potential as the donor species animal source of cells, tissues and organ for safety, effectiveness, ethical, and economic reasons. Their favorable breeding characteristics (large litters and rapid maturation) and feasibility for genetic manipulation to insert or delete genes also help the development of clinical xenotransplantation. The porcine organs and biological systems as well as their functions are very close to those in humans in term of anatomical and physiological similarities. Porcine proteins and tissues have already been applied in clinics, such as prosthetic porcine heart valves, heparin for anti-coagulation, factor VIII to treat hemophilia, and porcine insulin to treat type 1 diabetes. Xenogeneic cell therapy using porcine cells as a donor source has several distinct advantages: First, from a well characterized and identified animal source, xenogeneic cells with specialized characteristics and functions could be isolated and ex vivo expanded from different specific tissues without the need to directed differentiation that is required by allogeneic human stem cells. And second, xenogeneic cells from porcine donors could be well manufactured by raising animals under strict quality controlled conditions and streamlining cell production process to provide safe tissues and consistent, safe cell preparations. The risk of pathogen transmission could be mitigated through raising animals under designated pathogen-free (DPF) conditions and producing cells with good manufacturing practices (GMP) system. Furthermore, precise and effective genetic engineering to genetically modify animals or porcine cells could be achieved by the development of mRNA-based expression and CRISPR-Cas9–based gene editing methodologies.

### Old Proposed Uses of Xenogeneic Cells for Treating Diseases

With the advantages of xenogeneic porcine cell therapy, various xenogeneic cell types isolated from different tissues have been tested in preclinical animal experiments and several therapies have advanced from pre-clinical safety and efficacy studies to human clinical trial.

### Xenogeneic islet cells for type 1 diabetes (T1D)

It was estimated that more than 463 million people worldwide suffer from diabetes, rising to 10.2% (578 million) by 2030 and 10.9% (700 million) and by 2045 global health expenditure on diabetes was estimated to be USD 727 billion. T1D caused by destruction of insulin-producing pancreatic islet beta-cells due to irreversible immune-mediated attacks occurs predominantly in children and they require lifelong insulin injection therapy, but tight glucose control remains difficult. Even with optimal insulin therapy, some patient’s unstable insulin levels contribute to end stage micro- and
macro-vascular injury and subsequently contribute to end-stage organ failure such as neuropathy, nephropathy, retinopathy and peripheral vascular disease as well as severe hypoglycemic events, causing substantial morbidity and mortality\textsuperscript{23,24}. Islet cell transplantation is a valuable alternative to whole pancreas transplantation to treat diabetes and reduce the life-threatening hypoglycemia unawareness in patients with T1D\textsuperscript{23,24}. Therefore, there is highly unmedical need for T1D patients with frequent hypoglycemic episodes and extreme glycemic lability, so-called “brittle disease.” Cell-based islet cell transplantation therapy with the Edmon- ton protocol and proper immunosuppression regimens has been demonstrated to long-term insulin independence and decreased risk of life-threatening hypoglycemia for many patients\textsuperscript{23,24}. Although allogeneic islet cell transplantation has been clinically proved a safe and effective treatment for patients with labile T1D, but the shortage of suitable human donor islet cells severely limits the availability of this treat- ment. Alternative allogeneic stem cell-derived islet cell replacement therapy has been tested in in human clinical trial with inconsistent results\textsuperscript{25}. Paucity of human organ donors has led to the consideration of potential alternative sources of islet cells, with porcine islet cells being attractive candidates for cell therapy. Since porcine insulin has long been used and functions in humans to treat patients before recombinant human insulin became available due to high similarity in porcine insulin protein sequence with only one amino acid residue difference to human insulin, xenogeneic porcine islet cell therapy has long been proposed to treat T1D\textsuperscript{26–28}. Porcine islet cell xenotransplantation has been investigated as a potential bridge or the ultimate treatment for T1D in decades with substantial progresses in both preclinical and clinical studies. Xenogeneic islet cell therapy could become a clinically applicable treatment with proper clinically applicable immunosuppression regimens or efficient bio-compatible matrix encapsulation devices that permit diffusion of oxygen and nutrients and prevent transplanted islet cells from the host immune attacks\textsuperscript{26,27}. Preclinical pig-to-nonhuman primate transplantation models have been studied and the first long-term graft survival (>6 month) of pig islet cells in non-human primates (NHPs) has been demonstrated\textsuperscript{29–31}. Subsequent study further confirmed reproducible curative potential in NHP model that pig islet grafts survived and maintained normoglycemia for >6 months with the longest up to 603 days\textsuperscript{32}. The clinical studies with xenogeneic porcine islet cells demonstrated the cell survival and function in the human body with no noted serious adverse events, but these clinical islet cell xenotransplantation trials have not shown to durably prevent severe hypoglycemia while maintaining tight glycemic control in T1D patients\textsuperscript{28,33}.

Xenogeneic hepatocytes for liver failures. Acute liver failure and end-stage liver diseases cause the loss of liver functions in carbohydrate, protein, and lipid metabolism as well as the synthesis of coagulation factors, complements, and acute phase proteins. Thus, severe liver failure results in impaired coagulation, hepatic encephalopathy and extrahepatic organ failures with high mortality rate\textsuperscript{34}. Orthotopic liver transplantation (OLT) is recommended with proven clinical benefits and long-lasting effects as a standard of care for acute liver failure, end-stage liver disease, or metabolic defects of the liver-based metabolic disorders. However, because of the donor liver shortage, there is a significant waiting list for patients to get benefit from OLT. A potential solution to dress the shortage of organs for liver transplantation is allogeneic hepatocyte transplantation. Clinical hepatocyte transplantation studies have proven the safety and short-term efficacy of allogeneic hepatocytes in which transplanted cells provide the missing/impaired hepatic function once engrafted into the recipient’s liver, but still its clinical applications require stable supply of allogeneic hepatocytes, high cell engraftment, and long-lasting effects\textsuperscript{35–37}. Xenotransplantation of hepatocytes has numerous potential advantages including only moderate invasiveness of the transplant procedure, low morbidity and high safety, a potentially unlimited supply of cells, the option to protect the cells by encapsulation, the use of genetically modified cells, and the possibility of cryopreserving hepatocytes. The xenogeneic hepatocyte therapy would provide temporary liver support to stabilize metabolic functions while the patient waits for an allotransplant or the regeneration of their own liver. Xenogeneic hepatocyte therapy has been tested in NHP model by transplanting porcine hepatocytes into the spleens of cynomolagus monkeys using conventional immunosuppression to control rejection and xenogeneic hepatocytes functioned for more than 80 days and, following re-transplantation, for more than 253 days based on the detection of porcine albumin in the recipients’ circulation\textsuperscript{38}.

Xenogeneic nerve cells for Parkinson’s disease. Parkinson’s disease (PD), the second most common age-related neurodegenerative disease after Alzheimer’s disease, is a movement disorder due to the death of dopaminergic neurons in the substantia nigra because of misfolding of proteins and dysfunction of the ubiquitin-proteasome pathway or mitochondrial dysfunction and oxidative stress\textsuperscript{39}. Current PD medications only provide symptomatic relief, but have no effects in stopping or even reversing dopaminergic neuron degeneration to improve outcomes\textsuperscript{40}. Fetal/embryonic mesencephalic tissue containing dopamine cells were used to treat patients with the motor disability of advanced Parkinson’s disease by implanting tissues into the caudate and putamen and neurological improvement to some patients with advanced PD was observed\textsuperscript{41}. Induced pluripotent stem cells (iPSCs) are a promising cell source to derive dopaminergic progenitors to treat PD patients, which have been tested in a primate PD model, indicating that human iPSC-derived dopaminergic progenitors are clinically applicable for the treatment of patients with PD\textsuperscript{42}. A single patient study using autologous, iPSC-derived dopaminergic progenitor cells for the treatment of progressive idiopathic PD showed cell
survival and possible motor function benefit. Although these exploratory studies using human fetal tissue allografts or stem cell derived dopaminergic neurons suggest that cell therapies have the potential to become an effective treatment for PD patients. However, because of the limited availability of human fetal tissue and ethical concern and the difficulties in controlling the differentiation of stem cells, the use of xenogeneic donor tissue was considered and tested in human clinical trials. The unilateral striatal transplantation of porcine fetal neural cells into PD patients has shown to be safe and clinically improve patient outcomes. Long-term (over 7 months) graft survival was found with the presence of pig dopaminergic neurons and other pig neural and glial cells in a PD patient with unilateral transplantation of fetal pig neural cells into the caudate-putamen brain region through a post-mortem histological analysis. Encapsulated Porcine choroid plexus cells from neonatal porcine choroid plexus (CP), an organ that secretes cerebrospinal fluid containing various types of neurotrophic and neuroprotective factors, was first demonstrated to improve neurological functions without requiring immunosuppression in PD disease NHP model. However, a randomized, double-blind, placebo-controlled human trial on intra-striatal transplantation of encapsulated porcine choroid plexus cells for PD patients showed no evidence that the treatment brought significant clinical benefit in patients with moderately advanced Parkinson’s disease.

### Immune-Mediated Barriers for Successful Clinical Xenogeneic Cell Therapy

The successful clinical application of xenogeneic cell therapy faces less immunological obstacles than organ xenotransplantation due to their avascularity nature (the vasculature of implanted xenogeneic cells is formed by the recipient vessels), but there are still formidable xenogeneic immune responses toward xenogeneic cells, first by innate and later by adaptive immunity, stopping cell engraftment, functions and survival. Immune cell infiltration of tissue and solid organ xenografts starts with neutrophils as an early responding cell population, followed by macrophages and T cells. The innate immune system, which is composed mainly of phagocytic cells (monocytes, macrophages and neutrophils), natural killer (NK) cells, as well as inflammatory mediator releasing granulocytes (basophils, eosinophils and mast cells), recognizes non-selfness of xenogeneic cells, like pathogen-associated molecular patterns (PAMPs), leading to the activation of innate immune cells and complement to boost immune responses to eradicate xenogeneic cells. Neutrophils are directly activated by xenogeneic cells and indirectly through xenoreactive natural antibodies (XNA) and complement to boost immune responses to eradicate xenogeneic cells. Macrophages express signal-regulatory protein-a (SIRPa), an inhibitory receptor, which recognizes a ubiquitously expressed cell surface protein CD47 “don’t eat me for autologous cells” and controls phagocytic activity of macrophages preventing phagocytosis of autologous cells. The porcine CD47-human SIRPa interaction is not effective to inhibiting macrophage phagocytosis. Therefore, macrophage-mediated rejection leads to destruction of xenogeneic cells. NK cells are activated by xenoreactive antibodies and the absence of human leukocyte antigen (HLA) for the inhibitory receptor CD94/NKG2A mechanisms to reject xenogeneic cells and human HLA-E/hubeta2m expression on xenogeneic cells could protect cells from NK cell-mediated cytotoxicity and inhibit the secretion of interferon (IFN)-gamma by NK cells. Humoral graft rejection is triggered by antibodies directed against the xenogeneic cell. These antibodies may be performed or produced de novo by B cells after recognition of xenoeptopes. T-cell-mediated immunity play a critical role in rejecting xenogeneic cells, which is activated by innate immune cells or direct binding to porcine swine leukocyte antigen (SLA) class 1 and 2 molecules, or indirectly by recipient antigen-presenting cells (APCs) expressing MHCs with processed xenoantigens. Indirect T-cell activation triggered by xenogeneic cells is suggested to be more immunogenic than by allogeneic cells, because the large number of xenoantigen peptides are presented by human antigen presenting cells due to interspecies incompatibility of CD47. T cell-mediated cytotoxicity toward xenogeneic cells is mediated predominantly by xenoreactive CD4+ T cells through the Fas/FasL pathway of apoptosis or other effector mechanisms. The expression of LEA29Y, a human CTLA4-Ig derivative that binds human B7.1/CD80 and B7.2/CD86 with high affinity and is thus a potent inhibitor of T cell co-stimulation, on xenogeneic cells protects xenogeneic cells from human T cells. Incidentally, the anti-CTLA4 antibody with the opposite action of CTLA4-Ig derivative is currently used in cancer immunotherapy and has demonstrated substantial and durable effects in patients with advanced melanoma. This implies that xenogeneic cell could activate the immune responses suppressed by CTLA4 and this function could be used as a way to enhance the priming of immune active T cells.

In addition to cellular rejection, transplanted xenogeneic cells are also the targets of host humoral immune responses as in the case of transplanted porcine islet cells that faces instant blood-mediated inflammatory reaction with the activation of platelets, the coagulation and the complement systems, resulting in islet cell loss. Furthermore, after cell administration, hypoxia due to slow or poor neovascularization for implanted cells also causes the loss of cells. However, if utilizing xenogeneic cells as a drug, despite these barriers, the cells can be administered repeatedly to replenish the loss of cells and maintain the therapeutic effects.

### Novel Uses of Xenogeneic Cells

The major uses of cell therapy have been focus on cell replacement to restore the function of failure tissues with the anticipated cell functions. However, the multiple
properties of cells beyond anticipated cell functions could be further explored as mechanisms of action for working as therapeutic cell drugs for all autologous, allogeneic and xenogeneic cell therapies. The immunologic barriers have prevented the successful clinical application as proved therapies since the inception of xenotransplantation. However, if the immunological barriers incurred by xenogeneic cells could be tempered, discounted and even taken advantage of, xenogeneic cells could be repeatedly administered to maintain the effectiveness as a drug before the previous cells are completely eliminated due to rejection. More novel uses of xenogeneic cells with multiple cell properties would be possible and make them a new class of drugs to improve patients' outcomes.

**Xenogeneic mesenchymal stroma cell for inflammatory diseases.** Allogeneic mesenchymal stem/stromal cells or medicinal signaling cells (MSCs) contain regenerative, anti-inflammatory, and immune modulatory properties have demonstrated promising therapeutic potential in clinical trials as a novel and safe cell therapy to treat a variety of diseases\(^{30,61}\). In a randomized, double-blind, parallel-group, placebo-controlled study, allogeneic, expanded, adipose-derived MSCs for patients with Crohn's disease and treatment-refractory, draining complex perianal fistulas showed that MSCs appeared to promote healing of perianal fistulas\(^{62}\). Allogeneic MSCs infusion also was shown to be an effective therapy to improve survival for patients with steroid-refractory acute graft-versus-host disease following hematopoietic cell transplantation\(^{63,64}\). Several studies also have demonstrated that systemic administration of allogeneic MSCs was safe with favorable outcome in the treatment for acute respiratory distress syndrome (ARDS)\(^{65}\). Furthermore, a pilot study in China demonstrated that the intravenous infusions of donor allogeneic mesenchymal stem cells in seven severe Coronavirus disease 2019 (COVID-19) patients who had fever, shortness of breath, cough, and oxygen saturation at rest <95% improved functional outcomes of patients as well as changes of inflammatory and immune function levels and the majority of patients showed negative results for the SARS-CoV-2 nucleic acid test over a week or two after MSC infusion\(^{66,67}\).

As for xenotransplantation point of view, there are a lot of animal studies that use human MSCs to treat animals in different disease models without immunosuppression, suggesting that xenogeneic MSCs could still function, regenerate and differentiate as well as be engrafted into the recipients across the species barrier\(^{68,69}\). Xenogeneic MSCs can immuno-modulate human T cells through induction of apoptosis or anergy, or cause T cell phenotype switching with induction of regulatory T cells and show no more immunogenic than allogeneic MSC\(^{68,70}\). Xenogeneic mesenchymal stem cells (MSC) derived from porcine source was shown to suppress human peripheral blood lymphocyte (hPBLs) proliferation through FasL and TGF-beta1 mediated pathways in vitro\(^{71}\). Xenogeneic transplantation of porcine MSCs protected against renal injury and reduced inflammation in lupus nephritis prone mice\(^{72}\). Transplantation of coencapsulated pig islet cells with porcine adipose or bone marrow MSCs was shown to improve oxygenation and neangiogenesis of encapsulated islet cells in subcutaneous tissue in a primate preclinical model\(^{69}\). Thus If xenogeneic MSCs could be demonstrated to have immunomodulatory effects for inflammatory diseases comparable to that of human MSCs, they have the potential to become a therapeutic agent.

**Xenogeneic urothelial cells for cystitis.** Cystitis, the inflammation of bladder, is the results of urothelial injury due to physical and chemical stress or microbial infection\(^{73}\). Hemorrhagic cystitis, resulting in bleeding from the bladder mucosa, mainly caused by anticancer chemotherapy or radiotherapy for the treatment of pelvic malignancies\(^{74}\). Cyclophosphamide (CPP, a chemotherapeutic drug)-induced hemorrhagic cystitis occurs due to the toxic metabolite (acrolein) of cyclophosphamide concentrated in the bladder, which is a reactive, unsaturated aldehyde that induces the production of reactive oxygen species and nitric oxide to damage urothelium\(^{75,76}\). CPP-induced hemorrhagic cystitis is treated prophylactically by measures such as hyperhydration, and bladder irrigation, or detoxification with 2-mercaptoethane sodium sulphonate or treated with oral aminocaproic acid, estrogen, sodium pentosane polysulfate, endoscopic laser coagulation, intramural orgotein (free radical scavenger). Intravesical regimens of alum and formalin, hyperbaric oxygen, urinary diversion and even cystectomy are used, but their efficacy is variable\(^{73,77,78}\). A xenogeneic urothelial cell-based cyotherapy strategy was proposed to treat this disease. In a mouse CPP-induced cystitis model, the intravesical instillation of xenogeneic urothelial cells for porcine urothelium into bladders was shown to reduce the detrimental injury caused by CPP injection, with less injury-induced cell proliferation, cell apoptosis and the maintenance of urothelial integrity\(^{79}\). The host immunity is triggered to reject xenogeneic cells, but transplanted cells are able to protect urothelium from the toxic chemical attack, not only in decreasing the damages caused by CPP, but also preventing cell death that could be induced by CPP. Furthermore, if xenogeneic urothelial cells could be applied as a drug, repeated administration could be performed to maintain the therapeutic effect. There are several intravesical agents used to treat various degree of hemorrhagic cystitis such as alum (aluminum ammonium sulfate or aluminum potassium sulfate), hyaluronic acid and even formalin to contain hemorrhage in the mucosa and submucosa\(^{80,82}\). Intravesical instillation of xenogeneic urothelial cells represents a novel safe and effective therapeutic potential option for urothelial injury based cystitis.

**Xenogeneic tissue specific cells as an immunostimulatory agent for cancer immunotherapy.** Rejection of transplanted xenogeneic cells first starts cell cytolysis mediated by
granulocytes and monocytes, which is activated by surface non-self xenoantigens from innate immunity. In addition to the innate immune response, xenogeneic cells are also rejected by the adaptive immune system involving xenoreactive antibody producing B cells and xenoreactive CD4+ or CD8+ T-cells. Xenogeneic cells are able to stimulate both innate and adaptive immune responses. In the other hand, although tumor cells express non-self neoantigens that activate multiple cell types including innate immune cells and adaptive immune cells to eradicate tumor cells, clinically detected tumor cells could escape anti-tumor immunity and grow progressively by creating an immunosuppressive tumor microenvironment through multiple mechanisms. Multiple immunosuppression regimes are intensively studied to overcome immunological barriers of xenogeneic cell therapy with immunosuppressive agents such CTLA4-Ig to induce T cell co-inhibitory pathway and anti-IL-2 R to block T cell proliferation and activation. Their opposite agents: anti-CTLA4 antibody to block T cell co-inhibitory pathway and IL-2 to induce T cell proliferation and activation are currently standard care of cancer immunotherapy to boost the immune system to fight cancers. Therefore, the use of xenogeneic cells as an immunostimulatory agent for cancer immunotherapy was proposed as a new class of anti-cancer agents. General xenogeneic immune responses have been investigated to treat human cancers. Xenogeneic polyantigenic vaccine prepared from murine melanoma B16 and carcinoma LLC cells used in 60 stage IV colorectal cancer patients was demonstrated to be safe and benefit patients associated with vaccine-induced, proinflammatory immune responses. Xenogeneic immunization with homologous antigens derived from a different species (xenoantigens) to overcome immune ignorance and tolerance induced by tumor cells effectively boost antitumor immunity. Xenogeneic DNA immunization with xenogeneic human TRP-2 (hTRP2) DNA immunization was shown to prevent local recurrence and the development of metastases in a mouse model of minimal residual melanoma by a mechanism requiring CD4(+) and CD8(+) T cells. Xenogeneic human tyrosinase plasmid DNA vaccination of dogs with advanced malignant melanoma showed potentially therapeutic activity. In human clinical trials on malignant melanoma patients, DNA vaccines encoding xenogeneic melanosomal antigens (tyrosinase, gp100) induced CD8(+) T-cell responses, and epitope spreading of CD8+ T cell response was observed. However, the clinical benefit for this xenogeneic vaccine approach has not been confirmed yet.

We have hypothesized a novel therapeutic xenogeneic cell cancer immunotherapy approach using xenogeneic tissue specific cells of the same tumor origin, which have homologous protein expression as tumor cells to induce cross-reactive antitumor T-cells. This treatment modality combines both cell therapy and immunotherapy, not only providing functional cells for tissue regeneration and repair, but also inducing immune responses that can eradicate tumors.
but also activating innate and adaptive rejection immunity to remove non-self xenogeneic tissue specific cells. The xenogeneic rejection immune responses share similar features for antitumor immunity through either tumor cell intrinsic or extrinsic immunomodulatory mechanisms to promote cancer immune cycle\(^9\). We have tested this novel cancer immunotherapy approach on bladder cancer in pre-clinical mouse models\(^8\). First bladder cancer immunotherapy, intravesical bacillus Calmette-Guérin (BCG, a live attenuated form of Mycobacterium bovis) immunotherapy is the standard of care for patients with high-grade (HG), intermediate and high risk non-muscle invasive bladder cancer (NMIBC) after complete transurethral resection of the tumor\(^9\). BCG is the most effective agent in the treatment of NMIBC, but however, the exact mechanism of action of BCG in relation to its antitumor effect is still mainly unclear since its introduction in 1976 by Morales et al\(^10\). Despite that the exact antitumor mechanism of intravesical instillation of BCG is unknown, a set of local immune responses such as the induction of CD4 T cell infiltration, which may persist for a number of months, correlate with tumor suppression effect\(^101,102\), suggesting that anti-bacteria immune responses induce bystander antitumor immune responses. This bystander antitumor immune response could be exploited using xenogeneic immune responses as another way to activate the host immune system in order to find more effective and durable immunotherapy. In mouse bladder cancer models, we showed that intravesical administration of xenogeneic urothelial cells isolated and expanded from porcine urothelium inhibits tumor growth and progression as well as extends survival and the combination with standard care chemotherapy is more efficacious than either single therapy through activation of host antitumor immune responses\(^9\). This novel xenogeneic cell immunotherapy strategy has the potential to open a new class of cancer immunotherapeutic agents for cancers of different tissue types using xenogeneic tissue specific cells of the same tissue types because of the advantages of xenogeneic cells as a form of cell medicine.

**Conclusion**

Remarkable pre-clinical and clinical research progress have been made with demonstration of efficacy and safety in the development of utilizing xenogeneic cells as a therapeutic drug to treat a varieties of diseases using different types of xenogeneic tissue-specific cells for old proposed and novel applications (Fig. 1). Immunological barriers of xenogeneic cell therapy still require the development of suitable immunosuppression regimes or induced tolerance and multiple genetic engineering. However, if barriers could be accepted such as the applications with xenogeneic MSCs and urothelial cells or even more taken advantage of, turning into immunological booster like xenogeneic cell cancer immunotherapy, more potential uses of xenogeneic cells could be explored. However, there are still more formidable hurdles to be removed before meaningful xenogeneic cell clinical applications, regarding isolation, expansion and well characterization of xenogeneic cells from safe donor animals, improvement of cell engraftment, and most importantly, demonstration of significant and durable efficacy and long-term safety. We believe that xenogeneic cells provide a potential therapy to manage the body damages caused by diseases with mechanisms of action much different to small molecule drugs and protein drugs.

**Acknowledgments**

This work was supported by China Medical University Hospital grants (DMR-104-038 and DMR-104-045).

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Chih-Rong Shyr [https://orcid.org/0000-0003-4762-8877](https://orcid.org/0000-0003-4762-8877)

**References**

1. Arrighi N.3 - Stem Cells at the Core of Cell Therapy. In: Arrighi N, editor. Stem Cells: Elsevier; 2018. 73–100.
2. Guidance for Industry: Human Somatic Cell Therapy and Gene Therapy. I U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. March, 1998.
3. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517.
4. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–1737.
5. Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with crohn’s disease. Gastroenterology. 2018; 154(5):1334–1342 e4.
6. Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans; Guidance for Industry. U.S. Department of Health and Human Services. Food and Drug Administration, Center for Biologics Evaluation and Research. December, 2016.
7. Expedited Programs for Regenerative Medicine Therapies for Serious Conditions. Services. U.S. Department of Health and Human Services. Food and Drug Administration, Center for Biologics Evaluation and Research. February, 2019.
8. Guideline on xenogeneic cell-based medicinal products. European Medicines Agency. 2009.
9. Meier RPH, Muller YD, Balaphas A, Morel P, Pascual M, Seebach JD, Buhler LH. Xenotransplantation: back to the future? Transpl Int. 2018;31(5):465–477.
10. Ekser B, Li P, Cooper DKC. Xenotransplantation: past, present, and future. Curr Opin Organ Transplant. 2017;22(6):513–521.
11. Hawthorne WJ, Cowan PJ, Buhler LH, Yi S, Bottino R, Pierson RN, 3rd, Ahn C, Azimzadeh A, Cozzi E, Gianello P, Lakey JRT, et al. Third WHO global consultation on regulatory requirements for xenotransplantation clinical trials, Changsha, Hunan, China December 12-14, 2018: “The 2018 Changsha Communiqué” the 10-year anniversary of the international consultation on xenotransplantation. Xenotransplantation. 2019;26(2):e12513.
12. Cooper DKC, Gaston R, Eckhoff D, Ladowski J, Yamamoto T, Wang L, Iwase H, Hara H, Tector M, Tector AJ. Xenotransplantation—the current status and prospects. British Medical Bulletin. 2017;125(1):5–14.
13. Sykes M, Sachs DH. Transplanting organs from pigs to humans. Sci Immunol. 2019;4(41):eaau6298.
14. Manji RA, Menkis AH, Ekser B, Cooper DK. Porcine prothetic heart valves: the next generation. Am Heart J. 2012;164(2):177–185.
15. Mulloy B, Gray E, Barrowcliffe TW. Characterization of unfractionated heparin: comparison of materials from the last 50 years. Thromb Haemost. 2000;84(6):1052–1056.
16. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood. 1993;81(6):1513–1520.
17. Mann NP, Johnston DI, Reeves WG, Murphy MA. Human insulin and porcine insulin in the treatment of diabetic children: comparison of metabolic control and insulin antibody production. Brit Med J (Clinical research ed.). 1983;287(6405):1580–1582.
18. Spizzo T, Denner J, Gazda L, Martin M, Nathu D, Scobie L, Takeuchi Y. First update of the international xenotransplantation association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes—chapter 2a: source pigs—preventing xenozoonoses. Xenotransplantation. 2016;23(1):25–31.
19. Schuurman H-J. Regulatory aspects of clinical xenotransplantation. Int J Surg. 2015;23(Pt B):261–266.
20. Mori W, Ikeda K, Kometani K, Kato T, Morita J, et al. Xenotransplantation—the current status and prospects. British Medical Bulletin. 2017;125(1):5–14.
21. Sykes M, Sachs DH. Transplanting organs from pigs to humans. Sci Immunol. 2019;4(41):eaau6298.
22. Mulloy B, Gray E, Barrowcliffe TW. Characterization of unfractionated heparin: comparison of materials from the last 50 years. Thromb Haemost. 2000;84(6):1052–1056.
23. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood. 1993;81(6):1513–1520.
24. Mann NP, Johnston DI, Reeves WG, Murphy MA. Human insulin and porcine insulin in the treatment of diabetic children: comparison of metabolic control and insulin antibody production. Brit Med J (Clinical research ed.). 1983;287(6405):1580–1582.
25. Spizzo T, Denner J, Gazda L, Martin M, Nathu D, Scobie L, Takeuchi Y. First update of the international xenotransplantation association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes—chapter 2a: source pigs—preventing xenozoonoses. Xenotransplantation. 2016;23(1):25–31.
26. Park CG, Bottino R, Hawthorne WJ. Current status of islet xenotransplantation. Int J Surg. 2015;23(Pt B):261–266.
27. Coe TM, Markmann JF, Rickert CG. Current status of porcine islet xenotransplantation. Curr Opin Organ Transplant. 2020;25(5):449–456.
28. Matsumoto S, Abalovich A, Wechsler C, Wynyard S, Elliott RB. Clinical benefit of islet xenotransplantation for the treatment of type 1 diabetes. EBioMedicine. 2016;12:255–262.
29. Dufrane D, Goebls RL, Saliez A, Guiot Y, Gianello P. Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation. 2006;81(9):1345–1353.
30. Hering BJ, Wijkstrom M, Graham ML, Hardstedt M, Aasheim T, Ansite JD, Cheng J, Li W, Morán K, et al. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med. 2006;12(3):301–303.
31. Cardona K, Korbutt GS, Milas Z, Lyon J, Cano J, Jiang W, Bello-Laborn H, Hacquoir B, Stobert E, Gangappa S, Weber CJ, et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting co-stimulation pathways. Nat Med. 2006;12(3):304–306.
32. Shin JS, Kim JM, Kim JS, Min BH, Kim YH, Kim HJ, Jang JY, Yoon IH, Kang HJ, Kim J, Hwang ES, et al. Long-term control of diabetes in immunosuppressed nonhuman primates (NHP) by the transplantation of adult porcine islets. Am J Transplant. 2015;15(11):2837–2850.
33. Wang W, Mo Z, Ye B, Hu Pa, Liu S, Yi S. A clinical trial of xenotransplantation of neonatal pig islets for diabetic patients. Zhong nan da xue xue bao. Yi xue ban = journal of central south university. Med Sci. 2011;36(12):1134–1140.
34. Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure. N Engl J Med. 2020;382(22):2137–2145.
35. Iansante V, Mitry RR, Filippi C, Fitzpatrick E, Dhawan A. Human hepatocyte transplantation for liver disease: current status and future perspectives. Pediatr Res. 2018;83(1-2):232–240.
36. Dhawan A, Strom SC, Sokal E, Fox JJ. Human hepatocyte transplantation. Methods Mol Biol. 2010;640:525–534.
37. Fisher RA, Sokal E, Fox JJ. Human hepatocyte transplantation: worldwide results. Transplantation. 2006;82(4):441–449.

from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.
38. Nagata H, Nishitai R, Shirot A, Zhang JL, Koch CA, Cai J, Awwad M, Schuurman HJ, Christians U, Abe M, Baranowska-Kortylewicz J, et al. Prolonged survival of porcine hepatocytes in cynomolgus monkeys. Gastroenterology. 2007;132(1):321–329.
39. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39(6):889–909.
40. McFarthing K, Buff S, Ralaffot G, Dominey T, Wyse RK, Stott SRW. Parkinson’s disease drug therapies in the clinical trial pipeline: 2020. J Parkinson’s Dis. 2020;10(3):757–774.
41. Freed CR, Breeze RE, Rosenberg NL, Fink JS, Schumacher JM, Ellias SL, Palmer EP, Saint-Hilaire O. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson’s disease. N Engl J Med. 1992;327(22):1549–1555.
42. Kikuchi T, Morizane A, Doi D, Magotani H, Onoe H, Hayashi T, Mizuma H, Takara S, Takahashi R, Inoue H, Morita S, et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model. Nature. 2017;548(7669):592–596.
43. Schweitzer JS, Song B, Herrington TM, Park TY, Lee N, Ko S, Jeon J, Cha Y, Kim K, Li Q, Henchcliffe C, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson’s disease. N Engl J Med. 2020;382(20):1926–1932.
44. Fink JS, Schumacher JM, Ellias SL, Palmer EP, Saint-Hilaire M, Shannon K, Penn R, Starr P, VanHorne C, Kott HS, Dempsey PK, et al. Porcine xenografts in Parkinson’s disease and Huntington’s disease patients: preliminary results. Cell Transplant. 2000;9(2):273–278.
45. Deacon T, Schumacher J, Dinsmore J, Thomas C, Palmer P, Kott S, Edge A, Penney D, Kassissieh S, Dempsey P, Isacson O. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson’s disease. Nat Med. 1997;3(3):350–353.
46. Luo XM, Lin H, Wang W, Geany MS, Law L, Wynyard S, Shao H, Waldvogel H, Faull RL, Elliot RB, Skinner SJ, et al. Recovery of neuroglial functions in non-human primate model of Parkinson’s disease by transplantation of encapsulated neonatal porcine choroid plexus cells. J Parkinsons Dis. 2013;3(3):275–291.
47. Snow B, Mulroy E, Bok A, Simpson M, Smith A, Taylor K, Lockhart M, Lamb BJ, Frampton C, Schweder P, Chen B, et al. A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL(R) [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2019;61:88–93.
48. Vadori M, Cozzi E. The immunological barriers to xenotransplantation. Tissue Antigens. 2015;86(4):239–253.
49. Carvalho-Oliveira M, Valdivia E, Blaszczyk R, Figueiredo C. Immunogenetics of xenotransplantation. Int J Immunogenet. 2021;48(2):120–134.
50. Al-Mohanna F, Saleh S, Parhar RS, Khabar K, Collison K. Human neutrophil gene expression profiling following xenogeneic encounter with porcine aortic endothelial cells: the occult role of neutrophils in xenograft rejection revealed. J Leukoc Biol. 2005;78(1):51–61.
51. Griesemer A, Yamada K, Sykes M. Xenotransplantation: immunological hurdles and progress toward tolerance. Immunol Rev. 2014;258(1):241–258.
52. Karlsson-Parra A, Ridderstad A, Wallgren AC, Möller E, Ljunggren HG, Korsgren O. Xenograft rejection of porcine islet-like cell clusters in normal and natural killer cell-depleted mice. Transplantation. 1996;61(9):1313–1320.
53. Weiss EH, Lilienfeld BD, Muller S, Muller E, Herbach N, Kessler B, Waneke R, Schwinzer R, Seebach JD, Wolf E, Brem G. HLA-E/human beta2-microglobulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity. Transplantation. 2009;87(1):35–43.
54. Tahara H, Ide K, Basnet N, Tanaka Y, Ohdan H. Determination of the precursor frequency and the reaction intensity of xenoreactive human T lymphocytes. Xenotransplantation. 2010;17(3):188–196.
55. Yi S, Feng X, Wang Y, Kay TW, Wang Y, O’Connell PJ. CD4+ cells play a major role in xenogeneic human anti-pig cytotoxicity through the Fas/Fas ligand lytic pathway. Transplantation. 1999;67(3):435–443.
56. Bähr A, Käser T, Kemter E, Gerner W, Kurome M, Baars W, Herbach N, Witter K, Wünsch A, Talker SC, Kessler B, et al. Ubiquitous LEA29Y expression blocks t cell co-stimulation but permits sexual reproduction in genetically modified Pigs. PLOS One. 2016;11(5): e0155676.
57. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haenen IB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
58. Kirchhoff N, Shibata S, Wijkstrom M, Kulik DM, Salerno CT, Clemmings SM, Heremans Y, Galli U, Sutherland DE, Dalmaso AP, Hering BJ. Reversal of diabetes in non-immunosuppressed rhesus macaques by intraportal porcine islet xenografts precedes acute cellular rejection. Xenotransplantation. 2004;11(5):396–407.
59. Nilsson B. The instant blood-mediated inflammatory reaction after transplantation of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. EClinicalMedicine. 2020;19:100249.
63. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberter M, Dini G, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579–1586.

64. Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, Nemecek E, Neudorf S, Prasad V, Prockop S, Quigg T, et al. A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26(5):845–854.

65. Yip HK, Fang WF, Li YC, Lee FY, Lee CH, Pei SN, Ma MC, Chen KH, Sung PH, Lee MS. Human umbilical cord-derived mesenchymal stem cells for acute respiratory distress syndrome. Crit Care Med. 2020;48(5):e391–e399.

66. Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, Deng K, Zhang L, Zou B, Cheng B, Xu J. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15:39.

67. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, et al. Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–228.

68. Li J, Ezzelarab MB, Cooper DK. Do mesenchymal stem cells function across species barriers? relevance for xenotransplantation. Xenotransplantation. 2012;19(5):273–285.

69. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007;262(5):509–525.

70. Ezzelarab M, Ayares D, Cooper DK. The potential of genetically-modified pig mesenchymal stromal cells in xenotransplantation. Xenotransplantation. 2010;17(1):3–5.

71. Liu J, Lu XF, Wan L, Li YP, Li SF, Zeng LY, Zeng YZ, Cheng LH, Lu YR, Cheng JQ. Suppression of human peripheral blood lymphocyte proliferation by immortalized mesenchymal stem cells derived from bone marrow of Banna Minipig inbred-line. Transplant Proc. 2004;36(10):3272–3275.

72. Liu J, Lu X, Lou Y, Cai Y, Cui W, Wang J, Nie P, Chen L, Li B, Luo P. Xenogeneic transplantation of human placenta-derived mesenchymal stem cells alleviates renal injury and reduces inflammation in a mouse model of lupus nephritis. Biomed Res Int. 2019;2019:9370919.

73. Lee G, Romih R, Zupancic D. Cystitis: from urothelial cell biology to clinical applications. Biomed Res Int. 2014;2014:473536.

74. Bon K, Lichtensteiger CA, Wilson SG, Mogil J. Characterization of cyclophosphamide cystitis, a model of visceral and referred pain, in the mouse: species and strain differences. J Urol. 2003;170(3):1008–1012.

75. Korkmaz A, Oter S, Deveci S, Ozgurtas T, Topal T, Sadir S, Bilgic H. Involvement of nitric oxide and hyperbaric oxygen in the pathogenesis of cyclophosphamide induced hemorrhagic cystitis in rats. J Urol. 2003;170(6 Pt 1):2498–2502.

76. Korkmaz A, Topal T, Oter S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol. 2007;23(5):303–312.

77. Sandhu SS, Goldstraw M, Woodhouse CR. The management of haemorrhagic cystitis with sodium pentosan polysulphate. BJU Int. 2004;94(6):845–847.

78. Chong KT, Hampson NB, Corman JM. Early hyperbaric oxygen therapy improves outcome for radiation-induced hemorrhagic cystitis. Urology. 2005;65(4):649–653.

79. Huang CP, Chen CC, Tsai YT, Wu CC, Shyr CR. Intravesical administration of xenogeneic porcine urothelial cells attenuates cyclophosphamide-induced cystitis in mice. Cell Transplant. 2019;28(3):296–305.

80. Donahue LA, Frank IN. Intravesical formalin for hemorrhagic cystitis: analysis of therapy. J Urol. 1989;141(4):809–812.

81. Westerman ME, Boorjian SA, Linder BJ. Safety and efficacy of intravesical alum for intractable hemorrhagic cystitis: a contemporary evaluation. Int Braz J Urol. 2016;42(6):1144–1149.

82. Montgomery BD, Boorjian SA, Ziegelmann MJ, Joyce DD, Linder BJ. Intravesical silver nitrate for refractory hemorrhagic cystitis. Turk J Urol. 2016;42(3):197–201.

83. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Ex Med. 1994;180(1):1–4.

84. Gajewski TF, Schreiber H, Fu Y-X. Inmate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013(14):1014–1022.

85. Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30(6):507–519.

86. Thompson P, Badell IR, Lowe M, Turner A, Avila J, Azimzadeh A, Cheng X, Pierson RN, 3rd, Johnson B, Robertson J, et al. Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival. Am J Transplant. 2012;12(7):1765–1775.

87. Huang CP, Chen CC, Shyr CR. Xenogeneic cell therapy provides a novel potential therapeutic option for cancers by restoring tissue function, repairing cancer wound and reviving anti-tumor immune responses. Cancer Cell Int. 2018;18:9.

88. McCormick KA, Covelier AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Pancreatic cancer: update on immunotherapies and algenpantucel-L. Hum Vaccin Immunother. 2016;12(3):563–575.

89. Seledtsova GV, Shishkov AA, Kaschenko EA, Seledtsov VI. Xenogeneic cell-based vaccine therapy for colorectal cancer: Safety, association of clinical effects with vaccine-induced immune responses. Biomed Pharmacother. 2016;83:1247–1252.

90. Perales MA, Blachere NE, Engelhorn ME, Ferrone CR, Gold JS, Gregor PD, Noffz G, Wolchok JD, Houghton AN. Strategies to overcome immune ignorance and tolerance. Semin Cancer Biol. 2002;12(1):63–71.
91. Strioga MM, Darinskas A, Pasukoniene V, Mlynska A, Osta-
penko V, Schijns V. Xenogeneic therapeutic cancer vaccines as
breakers of immune tolerance for clinical application: to use or
not to use? Vaccine. 2014;32(32):4015–4024.

92. Srinivasan R, Wolchok JD. Tumor antigens for cancer immu-
notherapy: therapeutic potential of xenogeneic DNA vaccines.
J Transl Med. 2004;2(1):12.

93. Hawkins WG, Gold JS, Blachere NE, Bowne WB, Hoos A,
Lewis JJ, Houghton AN. Xenogeneic DNA immunization in
melanoma models for minimal residual disease. J Surg Res.
2002;102(2):137–143.

94. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J,
Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE,
Segal N, et al. Long-term survival of dogs with advanced
malignant melanoma after DNA vaccination with xenogeneic
human tyrosinase: a phase I trial. Clin Cancer Res. 2003;9(4):
1284–1290.

95. Wolchok JD, Yuan J, Houghton AN, Gallardo HF, Rasalan TS,
Wang J, Zhang Y, Ranganathan R, Chapman PB, Krown SE,
Livingston PO, et al. Safety and immunogenicity of tyrosinase
dNA vaccines in patients with melanoma. Mol Ther. 2007;
15(11):2044–2050.

96. Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z,
Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz
GR, Carvajal RD, et al. Immunologic response to xenogeneic
gp100 DNA in melanoma patients: comparison of particle-
mediated epidermal delivery with intramuscular injection. Clin
Cancer Res. 2010;16(15):4057–4065.

97. Chen Daniel S, Mellman I. Oncology meets immunology: the
cancer-immunity cycle. Immunity. 2013;39(1):1–10.

98. Huang CP, Wu CC, Shyr CR. Combination of novel intrave-
sical xenogeneic urothelial cell immunotherapy and che-
motherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models. Cancer Immunol Immunother.
2021;70(5):1419–1433.

99. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Com-
perat E, Hernandez V, Kaasinen E, Palou J, Roupret M, van
Rhijn BW, et al. EAU guidelines on non-muscle-invasive
urothelial carcinoma of the bladder: update 2016. Eur Urol.
2017;71(3):447–461.

100. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus
Calmette-Guerin in the treatment of superficial bladder
tumors. J Urol. 1976;116(2):180–183.

101. Alexandroff AB, Jackson AM, O’Donnell MA, James K.
BCG immunotherapy of bladder cancer: 20 years on. Lancet.
1999;353(9165):1689–1694.

102. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-
Guerin versus mitomycin C for superficial bladder cancer: a
formal meta-analysis of comparative studies on recurrence
and toxicity. J Urol. 2003;169(1):90–95.